Form 4 for EBS Emergent BioSolutions Inc.
Accepted 2025-10-16 00:00:00 ET · period of report 2025-10-07 · accession 0001919170-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-16 | 2025-10-07 | EBS | Glessner Coleen | EVP, Quality, Ethics, CPL | S - Sale | $10.00 | -30.6K | 144.3K | -17% | -$306.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-07 | S | D | 30,608 | $10.00 | 144,319 | D | — | — | (F1) All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on December 2, 2024 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). (F2) All shares sold at an exact price of $10.00. |